Trial Profile
A study of effect of the first treatment choice (laser photocoagulation (LPC) or intravitreal ranibizumab (IVR)) on the prognosis of stage 4A retinopathy of prematurity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 28 Aug 2017 New trial record